Loading...
IPSC logo

Century Therapeutics, Inc.NasdaqCM:IPSC Stock Report

Market Cap US$405.8m
Share Price
n/a
1Y274.8%
7D-7.4%
1D-2.6%
Portfolio Value
​
View

Century Therapeutics, Inc.

NasdaqCM:IPSC Stock Report

Market Cap: US$405.8m

Century Therapeutics (IPSC) Stock Overview

A biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. More details

IPSC fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Risk Analysis

Has less than 1 year of cash runway

Makes less than USD$1m in revenue ($0)

Shareholders have been substantially diluted in the past year

Earnings are forecast to decline by an average of 7.6% per year for the next 3 years

+ 1 more risk

IPSC Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW491,113 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
AG
Agricola
491,113 investors already sharing narratives
View all narratives

Century Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Century Therapeutics
Historical stock prices
Current Share PriceUS$2.25
52 Week HighUS$3.04
52 Week LowUS$0.43
Beta1.56
1 Month Change0%
3 Month Change-0.88%
1 Year Change274.81%
3 Year Change-25.37%
5 Year Change-91.84%
Change since IPO-90.14%

Recent News & Updates

Recent updates

Analysis Article • Dec 17

There's No Escaping Century Therapeutics, Inc.'s (NASDAQ:IPSC) Muted Revenues Despite A 32% Share Price Rise

Century Therapeutics, Inc. ( NASDAQ:IPSC ) shareholders have had their patience rewarded with a 32% share price jump in...
Analysis Article • Nov 30

We're Keeping An Eye On Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Oct 08

There Is A Reason Century Therapeutics, Inc.'s (NASDAQ:IPSC) Price Is Undemanding

Century Therapeutics, Inc.'s ( NASDAQ:IPSC ) price-to-sales (or "P/S") ratio of 0.4x might make it look like a strong...
Seeking Alpha • Jun 20

Century Therapeutics: Cell Therapy Biotech With Expanded Potential Of CNTY-101

Summary Positive poster presentation results were released at ASCO 2024 from the phase 1 ELiPSE-1 study, which used CNTY-101 for the treatment of patients with relapsed/refractory CD19-positive non-Hodgkin lymphoma patients. The global non-Hodgkin Lymphoma market is expected to surge to $11 billion by 2029. Initiation of phase 1 CALiPSO-1 study, using CNTY-101 for patients with systemic lupus erythematosus, is expected in the 1st half of 2024; Data from this study is to be released 2nd half of 2024. A highly important thing about this company would be the Allo-Evasion technology incorporated into the iPSC-derived cell therapies, which not only improves the safety of patients but could mean improved responses. Read the full article on Seeking Alpha
Analysis Article • Mar 06

Century Therapeutics (NASDAQ:IPSC) Will Have To Spend Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Feb 01

Century Therapeutics: More Attention Doesn't Mean You Should Buy Into INK Cell Therapy

Summary Century Therapeutics is a biotech focused on developing engineered natural killer cells for cancer and rheumatologic conditions. Their first clinical product, CNTY-101, showed promising early data with a patient experiencing tumor shrinkage and a complete clinical response. However, Century Therapeutics has a limited cash position and needs to prove the efficacy of their therapies before being considered a confident investment. Read the full article on Seeking Alpha
Analysis Article • Oct 23

We're A Little Worried About Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Aug 25

Century Therapeutics receives IND clearance for allogeneic cell therapy candidate

Century Therapeutics (NASDAQ:IPSC) will begin a phase 1 study of its allogeneic cell therapy CNTY-101 by the end of the year after receiving Investigational New Drug clearance from the US FDA. CNTY-101 is under investigation for relapsed or refractory CD19 positive B-cell malignancies. In the ELiPSE-1 study, all patients will receive an initial standard dose of conditioning chemotherapy. Schedule A consists of a single-dose escalation of CNTY-101 and subcutaneous IL-2. Schedule B will evaluate a three-dose schedule per cycle of CNTY-101. CNTY-101 is derived from a clonal  induced pluripotent stem cell (iPSC) master cell bank that yields homogeneous product. Seeking Alpha's Quant Rating views Century (IPSC) as a hold with strong grades for profitability and momentum.

Shareholder Returns

IPSCUS BiotechsUS Market
7D-7.4%-2.3%0.8%
1Y274.8%35.8%20.6%

Return vs Industry: IPSC exceeded the US Biotechs industry which returned 35.9% over the past year.

Return vs Market: IPSC exceeded the US Market which returned 20.6% over the past year.

Price Volatility

Is IPSC's price volatile compared to industry and market?
IPSC volatility
IPSC Average Weekly Movement9.1%
Biotechs Industry Average Movement10.4%
Market Average Movement7.3%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.2%

Stable Share Price: IPSC has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: IPSC's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201878Brent Pfeiffenbergerwww.centurytx.com

Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases.

Century Therapeutics, Inc. Fundamentals Summary

How do Century Therapeutics's earnings and revenue compare to its market cap?
IPSC fundamental statistics
Market capUS$405.80m
Earnings (TTM)-US$107.78m
Revenue (TTM)n/a
0.0x
P/S Ratio
-3.8x
P/E Ratio

Is IPSC overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IPSC income statement (TTM)
RevenueUS$0
Cost of RevenueUS$86.19m
Gross Profit-US$86.19m
Other ExpensesUS$21.59m
Earnings-US$107.78m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-0.60
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did IPSC perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/12 03:42
End of Day Share Price 2026/07/10 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Century Therapeutics, Inc. is covered by 10 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Geoffrey MeachamBofA Global Research
Chen YangBofA Global Research
William MaughanCanaccord Genuity